Monopar Therapeutics Inc

MNPR

Company Profile

  • Business description

    Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

  • Contact

    1000 Skokie Boulevard
    Suite 350
    WilmetteIL60091
    USA

    T: +1 847 388-0349

    E: [email protected]

    https://www.monopartx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    16

Stocks News & Analysis

stocks

Oracle shares are up 87% in 2025. Is it a buy?

Oracle’s cloud database business is riding the AI wave.
stocks

Bumper crop to benefit ASX listed share

We raise our earnings forecast 11% for next year.
stocks

Is there a long-term buying opportunity in luxury stocks?

Our analysts think the recent wobble in revenue growth is cyclical, not structural.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,142.6019.700.22%
CAC 407,830.1123.48-0.30%
DAX 4023,527.05112.36-0.48%
Dow JONES (US)46,381.5466.270.14%
FTSE 1009,226.6810.010.11%
HKSE26,344.14200.96-0.76%
NASDAQ22,788.98157.500.70%
Nikkei 22545,493.66447.850.99%
NZX 50 Index13,145.984.440.03%
S&P 5006,693.7529.390.44%
S&P/ASX 2008,850.3018.700.21%
SSE Composite Index3,828.588.490.22%

Market Movers